Company: PRTA
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001559053-25-000009
Chunk: 170

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 170
---
 and development (“R&D”) expenses by program as regularly provided to the CODM (in thousands): Year Ended December 31,202420232022Birtamimab (NEOD001)$85,649 $68,831 $49,312 BMS-986446 (PRX005)264 10,063 14,444 PRX012116,359 102,767 41,990 PRX0195,035 7,703 9,117 Other R&D15,212 31,207 20,699 Total research and development$222,519 $220,571 $135,562 

3.Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:Level 1 —    inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets.Level 2 —    inputs are other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 —    inputs are unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying amounts reflected in the Consolidated Balance Sheets for cash equivalents, prepaid expenses and other current assets, accounts receivable, accounts payable and accrued liabilities, approximate their fair value due to their short-term nature. Based on the fair value hierarchy, the Company classifies its cash equivalents within Level 1. This is because the Company values its cash equivalents using quoted market prices. The Company’s Level 1 securities consisted of $440.3 million and $589.9 million in money market funds included in cash and cash equivalents at December 31, 2024, and 2023, respectively.

4.Composition of Certain Balance Sheet Items

Prepaid Expenses and Other Current AssetsPrepaid and